@article{da07eaa4e658418f8f5f419048b650a8,
title = "Response to: Eculizumab package insert recommendations for meningococcal vaccinations: Call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder",
abstract = "We thank Avasarala et al for their editorial on meningococcal infection prevention in patients with neuromyelitis optica spectrum disorder (NMOSD) receiving eculizumab. While we appreciate the Authors' concerns and agree that its manufacturers (Alexion) have a responsibility to promote optimal patient safety, it iscritical that clinicians treating patients with eculizumab adhere to the latest vaccination recommendations, consider individual risk profiles, and monitor patients for early signs of meningococcal disease.",
author = "Pittock, {Sean J.} and Ilene Weitz and Howard, {James F.} and Guido Sabatella and Sunil Mehta and Jeremy Franklin",
note = "Funding Information: Dr. Pittock reports grants from Grifols; other from Euroimmun; grants from the National Institutes of Health (NIH); grants, personal fees, and nonfinancial support from the Guthy-Jackson Charitable Foundation; grants from the Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other from MedImmune, Inc.; other from Astellas; personal fees from UCB, Inc.; personal fees from Hoffman/LaRoche AG; and grants, personal fees, nonfinancial support, and other from Alexion Pharmaceuticals, Inc., outside the submitted work. In addition, Dr. Pittock has a patent Patent# 8889102 (Application# 12-678350)—Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued; a patent Patent# 9891219B2 (Application# 12-573942)—Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued; a patent GFAP-IgG pending; a patent Septin-5-IgG pending; a patent MAP1B-IgG pending; a patent Kelch-like protein 11 pending; and a patent PDE10A pending. Dr. Weitz reports consulting fees and speaker honoraria from Alexion Pharmaceuticals. Dr. Howard has received research support from Alexion Pharmaceuticals, argenx BVBA, the Centers for Disease Control and Prevention (Atlanta, GA), the Muscular Dystrophy Association, the NIH (including the National Institute of Neurological Disorders and Stroke, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, and Ra Pharmaceuticals; consulting fees/honoraria from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, and Viela Bio Inc.; and nonfinancial support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, and Toleranzia. Drs. Sabatella, Mehta, and Franklin are employees of Alexion Pharmaceuticals.",
year = "2021",
month = jun,
doi = "10.1017/S1092852920001625",
language = "English (US)",
volume = "26",
pages = "195--196",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "3",
}